The market expects Establishment Labs Holdings Inc. (ESTA) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is ex ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38593 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) Brit ...

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Raj Denhoy - Chief Financial Officer Juan José Chacón-Quirós - Chief Executive Officer Conference Call Participants Young Li - Jefferies Anthony Petrone - Mizuho Group Josh Jennings - Cowen & Company Sam Eiber - BTIG Neil Chatterji - B. Riley George Sellers - Stephens Operator Good afternoon. Welcome to Establishment Labs’ Second Quarter 2023 Earnings Call. At this time, all partici ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38593 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) British V ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38593 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) British ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38593 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) British Virgin Islands No ...

Financial Data and Key Metrics Changes - Record revenue in Q4 2022 totaled $43.8 million, a 24% increase over Q4 2021, with growth of approximately 28% excluding foreign currency impacts [15][24] - For the full year 2022, revenue totaled $161.7 million, a 28% increase over 2021, with a 32% growth rate when excluding currency changes [15] - The company provided revenue guidance for 2023 in the range of $200 million to $210 million, representing estimated growth of 24% to 30% over 2022 [16][37] Business Line Data and Key Metrics Changes - Direct sales accounted for approximately 37% of sales in Q4 2022, with distributor sales making up the remainder [24] - The rollout of the Motiva Flora tissue expander continues to receive positive market feedback, with increasing adoption among surgeons [18] Market Data and Key Metrics Changes - Sales distribution in Q4 2022: Europe approximately 28%, Asia Pacific and Middle East 40%, and Latin America the balance, with Brazil accounting for about 14.6% of total quarterly sales [25] - The company expects regulatory approval for Motiva in China in the first half of 2023, following the lifting of COVID restrictions [21] Company Strategy and Development Direction - Establishment Labs aims to create a new category in breast aesthetics with Mia, targeting women who prefer minimally invasive procedures [12] - The company is focused on improving breast reconstruction and democratizing access to these services globally, with a long-term revenue goal of $500 million by 2026 [22][50] - The new manufacturing facility is expected to more than double production capacity, allowing the company to meet over half of the current global demand [47] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving growth targets, citing strong momentum in the business and expected contributions from new initiatives like Mia in China [39][50] - The company is preparing for a busy 2023, with significant events including the commercial launch of Mia and the Motiva launch in China [41] Other Important Information - R&D expenses for Q4 2022 increased to $6.5 million, while total operating expenses rose to $41.3 million, reflecting investments in growth initiatives [26][32] - The gross profit for Q4 2022 was $28.2 million, or 64.3% of revenue, impacted by foreign currency fluctuations [33] Q&A Session Summary Question: Infrastructure for U.S. and Mia launch in Europe - Management discussed the unique business model for Mia, emphasizing partnerships with selected clinics rather than traditional sales reps [42][43] Question: 2023 guidance and contributions from Mia and China - Management clarified that the 2023 guidance does not include U.S. revenue, but expects contributions from Mia and China to build throughout the year [55][56] Question: Launch progress of Mia in Japan - Management confirmed the first clinic partner in Japan and highlighted the importance of demonstrating the new consumer base for Mia [70][71] Question: Gross margin expectations - Management indicated that while initial launches may be margin dilutive, overall gross margins are expected to improve over time due to new products and geographic expansions [76][80] Question: Regulatory environment and potential for faster approval - Management stated it is too early to predict the timeline for U.S. approval but remains focused on the regulatory process [97]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38593 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) Briti ...

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Raj Denhoy – Chief Financial Officer Juan Jose Chacon-Quiros – Chief Executive Officer Conference Call Participants Anthony Petrone – Mizuho Group Josh Jennings – Cowen George Sellers – Stephens Marie Thibault – BTIG Neil Chatterji – B. Riley Securities Operator Good afternoon. Welcome to Establishment Labs' Third Quarter 2022 Earnings Conference Call. [Operator Instructions] I wi ...

Establishment Labs Holdings, Inc. (NASDAQ:ESTA) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Juan Jose Chacon Quiros - Founder and CEO Rajbir Denhoy - CFO Conference Call Participants Chris Cooley - Stephens Zach Weiner - Jefferies Josh Jennings - Cowen Marie Thibault - BTIG Philip Coover - Goldman Sachs Anthony Petrone - Mizuho Group Operator Good afternoon. Welcome to Establishment Labs' Second Quarter 2022 Earnings Call. At this time, all participants will be in a liste ...